Monoclonal antibodies in MS: Mechanisms of action
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The development of monoclonal antibodies (mAbs) presents an emerging, highly specific therapeutic strategy for the treatment of multiple sclerosis (MS). mAbs target selective molecules and have shown early promise, along with notable risks, in the treatment of MS and other immune-mediated diseases. The mechanism of action of the 4 mAbs under active investigation for MS (natalizumab, rituximab, alemtuzumab, and daclizumab) are reviewed, with a discussion of how mAb interaction with each target antigen may produce direct and indirect effects (proven and hypothesized) on immune cell activity, CNS-related inflammatory processes, and clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
Coles, A. J., Wing, M., Smith, S., Coraddu, F., Greer, S., Taylor, C., Weetman, A., Hale, G., Chatterjee, V. K., Waldmann, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02429-0 · Cited by 453
Cited by
Multiple sclerosis: risk factors, prodromes, and potential causal pathways
Ramagopalan, S. V., Dobson, R., Meier, U. C., & Giovannoni, G. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70094-6 · Cited by 548
Multiple Sclerosis: Pathogenesis and Treatment
Loma, I., & Heyman, R. (2011) · Current Neuropharmacology · doi:10.2174/157015911796557911 · Cited by 350
Therapeutic antibodies: Market considerations, disease targets and bioprocessing
Elvin, J. G., Couston, R. G., & van der Walle, C. F. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.12.039 · Cited by 237
“With a focus on immune cells, we note hat the actions of mAbs generally involve either (1) the binding of he Fv domain within the Fab region to the antigen, so blocking he interaction of the antigen with its target, or (2) binding to its arget followed by complement activation or antibody-dependent ellular cytotoxicit…”
BackgroundKallaur, A. P., Oliveira, S. R., Simão, A. N. C., Alfieri, D. F., Flauzino, T., Lopes, J., de Carvalho Jennings Pereira, W. L., de Meleck Proença, C., Borelli, S. D., Kaimen-Maciel, D. R., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9846-x · Cited by 75
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Milo, R. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613504021 · Cited by 38
Metadata
- Authors
- Bielekova, B., & Becker, B. L.
- Venue
- Neurology
- Published
- 2010-01-05
- Volume
- 74
- Issue
- 1_supplement_1
- Pages
- S31-40
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1985887343
- Cited by
- 110
- References
- 2
- FWCI
- 11.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monoclonal antibodies in MS: Mechanisms of action. https://app.cochat.ai/papers/10.1212/wnl.0b013e3181c97ed3
- The paper
- Bielekova, B., & Becker, B. L. (2010). Monoclonal antibodies in MS: Mechanisms of action. Neurology. https://doi.org/10.1212/wnl.0b013e3181c97ed3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.